Approval of the IL-12/23 antagonist in pediatric ulcerative colitis was supported by data from the phase 3 UNIFI Jr trial, demonstrating 52-week clinical remission and favorable tolerability.
Phase 3 SURPASS-ET data support the expanded indication of ropeginterferon alfa-2b-njft as the first new FDA-approved essential thrombocythemia therapy in nearly 3 decades.
Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.
The researchers found that the adjusted mean percentage change in body weight at the 24-month follow-up was −3.40% for the Mediterranean-style intervention and −3.51% for the control intervention. The ...
A healthy lifestyle in early childhood is associated with a reduced risk for inflammatory bowel disease (IBD), according to a study published online August 24 i ...
Effective atrial fibrillation management requires rate or rhythm control, anticoagulation based on risk scores, and lifestyle ...
FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk ...
A daily single-tablet combination of bictegravir and lenacapavir offers a simplified treatment option for virologically suppressed adults with HIV-1.
The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.
Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results